rtki cpd has been researched along with Prostatic Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (92.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bajo, AM; Carmena, MJ; Muñoz-Moreno, L; Prieto, JC; Schally, AV | 1 |
| Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE | 1 |
| Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L | 1 |
| Bromberg, ME; Colman, RW; Fusaro, M; Godoy, G; Kim, E; Liu, Y; Pixley, R | 1 |
| Chan, FL; Chang, C; Huang, J; Lee, YF; Lin, WJ; Messing, EM; Wilding, G | 1 |
| Chung, T; Dent, P; Hagan, MP; Hinman, D; McKinstry, R; Yacoub, A | 1 |
| Halgunset, J; Larsson, E; Skogseth, H | 3 |
| Halgunset, J; Holt, RU; Larsson, E; Skogseth, H | 1 |
| Follestad, T; Halgunset, J; Larsson, E; Skogseth, H | 1 |
| Angelucci, C; Iacopino, F; Lama, G; Sica, G | 1 |
| Bates, LF; Brackenbury, WJ; Ding, Y; Djamgoz, MB; Montano, X; Onganer, PU; Porter, LM | 1 |
| Guo, C; Luttrell, LM; Price, DT | 1 |
14 other study(ies) available for rtki cpd and Prostatic Neoplasms
| Article | Year |
|---|---|
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Topics: Androgens; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Growth Hormone-Releasing Hormone; Humans; Male; Neuroendocrine Cells; PC-3 Cells; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Tyrphostins | 2020 |
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins | 2009 |
Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Kininogen, High-Molecular-Weight; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tyrphostins | 2009 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins | 2002 |
Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling.
Topics: Adenocarcinoma; Autocrine Communication; Cobalt Radioisotopes; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Quinazolines; Tumor Cells, Cultured; Tyrphostins; X-ray Repair Cross Complementing Protein 1 | 2003 |
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrphostins; Urokinase-Type Plasminogen Activator | 2005 |
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Topics: Basement Membrane; Biological Assay; Carcinoma; Cell Movement; Collagen; Drug Combinations; Genistein; Humans; Laminin; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Plasminogen; Plasminogen Activators; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteoglycans; Quinazolines; Tyrphostins | 2006 |
Tyrosine kinase inhibitors alter adhesivity of prostatic cancer cells to extracellular matrix components.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Survival; Extracellular Matrix; Genistein; Humans; Integrins; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tyrphostins | 2006 |
Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Cell Line, Tumor; Gene Expression; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Tyrphostins | 2006 |
Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metalloproteases; Prostatic Neoplasms; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Transcription, Genetic; Tyrphostins; Urokinase-Type Plasminogen Activator | 2006 |
Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Leuprolide; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tyrphostins | 2006 |
Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.
Topics: Animals; Cell Movement; Epidermal Growth Factor; Ion Channel Gating; Male; Prostatic Neoplasms; Quinazolines; Rats; Sodium Channels; Tetrodotoxin; Tyrphostins; Up-Regulation | 2008 |
Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.
Topics: Cell Division; Dihydrotestosterone; Enzyme Inhibitors; Epidermal Growth Factor; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2000 |